Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Heparin sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Heparin Sodium 10 I.U./ml Flushing Solution is heparinised saline which is heparin dissolved in a salt water solution. Heparin is an anti-clotting agent and is produced naturally in the body. Heparin Sodium 10 I.U./ml Flushing Solution is used to wash and rinse the inside of catheters, cannulas and other surgical forms of tubing to ensure they do not become blocked while they are in use.
e Heparin Sodium 10 I.U./ml Flushing Solution Do not use Heparin Sodium 10 I.U./ml Flushing Solution if:
Heparin Sodium 10 I.U./ml Flushing Solution
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.
As there is a risk of antibody-mediated heparin-induced thrombocytopenia, platelet counts should be measured in patients receiving regular and repeated use of heparin flush solutions for longer than 5 days or earlier in patients with previous exposure to heparin. In patients who develop thrombocytopenia or paradoxical thrombosis, heparin treatment should be stopped immediately and heparin eliminated from all flushes and ports. Heparin induced thrombocytopenia (HIT) and heparin induced thrombocytopenia with thrombosis (HITT) can occur up to several weeks after discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT or HITT. Repeated flushing of a catheter device with heparin may result in a systemic anticoagulant effect. 4.5 Interaction with other medicinal products and other forms of interactions When an indwelling device is used for repeated withdrawal of blood samples for laboratory analyses and the presence of heparin or saline is likely to interfere with or alter results of the desired blood tests, the in situ heparin flush solution should be cleared from the device by aspirating and discarding a volume of solution equivalent to that of the indwelling venipuncture device before the desired blood sample is taken. 4.6 Fertility, pregnancy and lactation The safety of Heparin Sodium 10 I.U./ml Flushing Solution in pregnancy is not established, but the dose of heparin involved would not be expected to constitute a hazard. Heparin does not appear in breast milk. 4.7 Effects on ability to drive and use machines None stated. 4.8 Undesirable effects Used as directed, it is extremely unlikely that the low levels of heparin reaching the blood will have any systemic effect, however, there have been rare reports of immune-mediated thrombocytopenia and thrombosis in patients receiving heparin flushes.
Customer
Wockhardt UK Limited
Colours Used
Description
Heparin Flush Soln 10IU/ML Amp
Black
Item Code
106935/6
Keyline (Non-Printing)
Profile
As per the leaflet
Technical Info (Non-Printing)
Size
375mm x 148mm
Min.Point Size
Other
Market
UK
Language
English
Standard 624
Barcode Proof By
EVA
Proof No.
2
Date
27/09/2022
Body Text Fonts:
Helvetica Neue LT
Body Text Ctd.
Text Free Area (Non-Printing) Actual Min Point Size
8.5pt
Cirrus_Info_Box
Like all medicines, this medicine can cause side effects, although not everybody gets them, particularly when treatment is first started.
Heparin Sodium 10 I.U./ml Flushing Solution Keep this medicine out of the sight and reach of children.
What Heparin Sodium 10 I.U./ml Flushing Solution contains Heparin Sodium 10 I.U./ml Flushing Solution is heparinised saline which is heparin dissolved in a salt water solution. It is available as a sterile heparinised saline flush solution in one strength of 10 international units per ml. Each 5ml ampoule contains 50 international units of heparin sodium. The active substance is heparin sodium. The other ingredients are sodium chloride, water for injections, hydrochloric acid and sodium hydroxide. What Heparin Sodium 10 I.U./ml Flushing Solution looks like and contents of the pack Heparin Sodium 10 I.U./ml Flushing Solution is a colourless or straw-coloured liquid. The registered pack size is 10 glass ampoules. Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK Only) Please be ready to give the following information: Product Name Reference Number Heparin Sodium 10 I.U./ml Flushing Solution 29831/0112 This is a service provided by the Royal National Institute of Blind People. Marketing Authorisation holder and Manufacturer Marketing Authorisation holder: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK Manufacturer: CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF, UK. This leaflet was last revised in September 2022
106935/6
Pulmonary embolism has been reported as thromboembolic complications of heparin-induced thrombocytopenia. Heparin should be discontinued immediately in patients who develop thrombocytopenia. Hypersensitivity reactions to heparin are rare. They include urticaria, conjunctivitis, rhinitis, asthma, cyanosis, tachypnoea, feeling of oppression, fever, chills, angioneurotic oedema and anaphylactic shock. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. 4.9 Overdose symptoms None stated 5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Heparin Sodium 10 I.U./ml Flushing Solution, containing only 50 I.U. of sodium heparin per ampoule (5ml), is used for flushing indwelling cannulae. This is unlikely to produce blood levels of heparin having any systemic effect. 5.2 Pharmacokinetic properties None stated 5.3 Preclinical safety data There are no pre-clinical data of relevance to the prescriber which are additional to those already included in other sections. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sodium chloride Water for injections Hydrochloric acid 3M Sodium hydroxide 3M 6.2 Incompatibilities The following drugs are incompatible with heparin;
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.
Amikacin sulfate, gentamicin sulfate, netilmicin sulfate, pethidine hydrochloride, promethazine hydrochloride and tobramycin sulfate. Heparin and reteplase are incompatible when combined in solution. If reteplase and heparin are to be given through the same line this, together with any Y-lines, must be thoroughly flushed with a 0.9% saline or a 5% glucose solution prior to and following the reteplase injection. 6.3 Shelf life Unopened – 3 years From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. 6.4 Special precautions for storage Do not store above 25°C Store in the original package 6.5 Nature and contents of container 5ml clear glass ampoules. Carton contains 10 ampoules. 6.6 Special precautions for disposal Not applicable 7 MARKETING AUTHORISATION HOLDER Marketing Authorisation holder: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK 8 MARKETING AUTHORISATION NUMBER(S) PL 29831/0112 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 September 2007 10 DATE OF REVISION OF THE TEXT September 2022
106935/6
Customer
Wockhardt UK Limited
Colours Used
Description
Heparin Flush Soln 10IU/ML Amp
Black
Item Code
106935/6
Keyline (Non-Printing)
Profile
As per the leaflet
Technical Info (Non-Printing)
Size
375mm x 148mm
Min.Point Size
Other
Market
UK
Language
English
Standard 624
Barcode Proof By
EVA
Proof No.
2
Date
27/09/2022
Body Text Fonts:
Helvetica Neue LT
Body Text Ctd.
Text Free Area (Non-Printing) Actual Min Point Size
8.5pt
Cirrus_Info_Box
Heparin Sodium 10 I.U/ml flushing solution for maintenance of patency of intravenous devices (PL 29831/0112) comes as solution. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Heparin Sodium 10 I.U/ml flushing solution for maintenance of patency of intravenous devices (PL 29831/0112) is heparin sodium.
Medicines with the same active substance, strength and form include: Heparin Sodium 100 I.U./ml flushing solution for maintenance of patency of intravenous devices (Wockhardt UK Ltd) (PL 29831/0111). They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Heparin Sodium 10 I.U/ml flushing solution for maintenance of patency of intravenous devices (PL 29831/0112), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Heparin is an anticoagulant and acts by potentiating the naturally occurring inhibitors of thrombin and factor X (Xa).
Heparin Sodium 10 I.U./ml Flushing Solution is indicated in any clinical circumstances in which it is desired to maintain the patency of indwelling catheters/cannulae, attendant lines or heparin locks.
Heparin Sodium 10 I.U./ml Flushing Solution is not recommended for systemic use.
For cleaning indwelling cannulae.
Material to be used as a cannula flush (5ml; 50 units) every four hours or as required.
The very rare occurrence of established hypersensitivity to heparin is the only contraindication to Heparin Sodium 10 I.U./ml Flushing Solution.
Concomitant use of intravenous diclofenac with heparin (including low dose heparin) is contraindicated.
Caution should be exercised in patients with known hypersensitivity to low molecular weight heparins. Rigorous aseptic technique should be observed at all times in its use.
As there is a risk of antibody-mediated heparin-induced thrombocytopenia, platelet counts should be measured in patients receiving regular and repeated use of heparin flush solutions for longer than 5 days or earlier in patients with previous exposure to heparin. In patients who develop thrombocytopenia or paradoxical thrombosis, heparin treatment should be stopped immediately and heparin eliminated from all flushes and ports.
Heparin induced thrombocytopenia (HIT) and heparin induced thrombocytopenia with thrombosis (HITT) can occur up to several weeks after discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT or HITT.
Repeated flushing of a catheter device with heparin may result in a systemic anticoagulant effect.
When an indwelling device is used for repeated withdrawal of blood samples for laboratory analyses and the presence of heparin or saline is likely to interfere with or alter results of the desired blood tests, the in situ heparin flush solution should be cleared from the device by aspirating and discarding a volume of solution equivalent to that of the indwelling venipuncture device before the desired blood sample is taken.
The safety of Heparin Sodium 10 I.U./ml Flushing Solution in pregnancy is not established, but the dose of heparin involved would not be expected to constitute a hazard.
Heparin does not appear in breast milk.
None stated.
Used as directed, it is extremely unlikely that the low levels of heparin reaching the blood will have any systemic effect, however, there have been rare reports of immune-mediated thrombocytopenia and thrombosis in patients receiving heparin flushes. Pulmonary embolism has been reported as thromboembolic complications of heparin-induced thrombocytopenia. Heparin should be discontinued immediately in patients who develop thrombocytopenia.
Hypersensitivity reactions to heparin are rare. They include urticaria, conjunctivitis, rhinitis, asthma, cyanosis, tachypnoea, feeling of oppression, fever, chills, angioneurotic oedema and anaphylactic shock.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
None stated
Ask anything about Heparin Sodium 10 I.U/ml flushing solution for maintenance of patency of intravenous devices (PL 29831/0112). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.